MENU
BIIB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BIIB stock forecast, quote, news & analysis

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases... Show more

Industry: #Biotechnology
A.I.Advisor
published price charts
A.I.Advisor
Oct 29, 2026

Why Biogen (BIIB) Stock Is Up +10.8% in the Last 30 Days

Key Takeaways

  • BIIB shares climbed roughly +10.8% over the trailing 30 days, rising from a $227.07 close on September 29 to about $251.59.
  • Third-quarter 2026 results, reported on October 28, beat consensus, with revenue of $2.80 billion (up 11% year over year) and adjusted EPS of $2.62 versus the roughly $2.06 expected.
  • Biogen's Growth Portfolio revenue rose 49% to $1.26 billion and now represents about 63% of core pharmaceutical revenue, supported by the first full quarter of Apellis products.
  • The company raised the lower end of its full-year 2026 non-GAAP EPS guidance to a range of $12.20 to $13.00.
  • The advance extends beyond one month: the stock is up roughly 20% over the trailing quarter and about 44% year to date.
  • Get additional detail on Biogen's Price Targets, Earnings, and Forecast to see how analysts and data models view the name.
  • Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.

Biogen (BIIB) Company Overview and Market Position

Biogen Inc. is a Cambridge, Massachusetts-based global biotechnology company focused on discovering, developing, and delivering therapies for neurological and rare diseases. Its commercial portfolio spans multiple sclerosis treatments such as Tysabri and Vumerity, spinal muscular atrophy therapy Spinraza, Alzheimer's disease drug Leqembi (developed with Eisai), and the Friedreich ataxia treatment Skyclarys, alongside Qalsody and Zurzuvae. Through its May 2026 acquisition of Apellis, Biogen added the geographic atrophy treatment Syfovre and the complement inhibitor Empaveli to its portfolio. Investors follow the stock for its pipeline of neurology and immunology readouts, its efforts to transition away from a maturing multiple sclerosis franchise, and its ability to sustain revenue growth through newer products.

Biogen (BIIB) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Biogen shares advanced from a closing price of $227.07 on September 29, 2026 to approximately $251.59, a gain of roughly +10.8%. The move accelerated in the second half of October, with the stock climbing from about $233 in mid-October toward the mid-$250s after the company's third-quarter earnings release, before settling near the $251 area.

The quarterly picture is even stronger. From a close of $209.23 on July 29, 2026, the stock has risen about 20%, reflecting a sustained upward trend rather than a single-session spike. This multi-month advance is consistent with Biogen's year-to-date gain of roughly 44%, outpacing the broader market as the company's growth portfolio gained commercial traction.

What Drove BIIB Stock Price in the Last 30 Days

The primary catalyst was Biogen's third-quarter 2026 earnings report on October 28. The company posted revenue of $2.80 billion, up 11% year over year and ahead of consensus estimates of roughly $2.59 billion to $2.64 billion. Adjusted earnings per share of $2.62 exceeded the approximately $2.06 analysts had projected, representing a meaningful positive surprise.

Growth in newer products underpinned the beat. Spinraza revenue rose 23% to $461 million on rapid patient conversion to a high-dose regimen, while Leqembi in-market sales climbed 67% to $202 million and Skyclarys grew 34% to $178 million. Syfovre and Empaveli, acquired from Apellis, contributed a combined $243 million in their first full quarter, and management indicated the pair was tracking toward a roughly $1 billion annualized run rate. Biogen also raised the lower end of its 2026 non-GAAP EPS guidance to $12.20, citing business strength and better-than-expected acquisition integration.

The report was not without offsetting items. A GAAP net loss of $20.6 million reflected about $284 million in acquired in-process R&D charges tied primarily to the RayThera acquisition, and the legacy multiple sclerosis franchise continued to face competitive and formulary pressure. Nevertheless, analyst actions around the quarter leaned constructive, including a Buy rating from Piper Sandler and reiterated coverage from other firms, reinforcing investor sentiment.

What Drove BIIB Stock Performance Over the Last Quarter

Over the trailing quarter, Biogen's advance has been driven by a broader narrative of a return to growth. The May 2026 completion of the Apellis acquisition diversified the revenue base beyond neurology into ophthalmology and nephrology, and integration has proceeded faster than initially anticipated, with management targeting $250 million in run-rate cost synergies by the end of 2027. Strong commercial execution across Spinraza, Leqembi, Skyclarys, and the acquired products has shifted the revenue mix decisively toward the growth portfolio, which now accounts for nearly two-thirds of core pharmaceutical revenue.

Investor enthusiasm has also been supported by a rich late-stage pipeline. Management has guided toward multiple registrational readouts over the coming quarters, including Phase 3 data for litifilimab in systemic lupus erythematosus and later readouts for felzartamab and zorevunersen. This combination of improving commercial momentum and near-term catalysts helped the stock sustain its upward trajectory through the quarter.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a platform that operates hundreds of bots across thousands of tickers. Rather than displaying every available strategy, the page surfaces only the top-performing and most relevant bots, allowing users to focus on signals that have demonstrated recent strength. These bots vary in strategy, timeframe, and performance metrics, so traders can review approaches that align with their own objectives and risk preferences. For investors seeking a data-driven complement to fundamental research, exploring the Trending AI Robots section can offer additional perspective on current market positioning.

BIIB Stock Forecast Drivers: What Investors Should Watch Next

Several factors are likely to shape Biogen's near-term outlook. The December readouts for litifilimab's two Phase 3 systemic lupus erythematosus studies represent a key pipeline catalyst, with subsequent data expected for felzartamab and, later, zorevunersen in Dravet syndrome. On the commercial side, investors will monitor whether Leqembi and the Apellis products sustain their growth trajectories and whether formulary and competitive pressures on the multiple sclerosis franchise stabilize. Execution on cost synergies, debt repayment, and the full-year 2026 guidance range of $12.20 to $13.00 in non-GAAP EPS will also be closely watched, alongside any updates on regulatory timelines and macroeconomic conditions affecting the biotech sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for BIIB with price predictions
Nov 16, 2026

Momentum Indicator for BIIB turns positive, indicating new upward trend

BIIB saw its Momentum Indicator move above the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 55 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 165 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

The Aroon Indicator entered an Uptrend today. In 124 of 199 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Bearish Trend Analysis

The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 18 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 58 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 43 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.947) is normal, around the industry mean (-1.421). P/E Ratio (43.724) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 4%. MIRA experienced the highest price growth at 2%, while SCLX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 32
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 25 (-100 ... +100)